JP2020512977A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512977A5
JP2020512977A5 JP2019553068A JP2019553068A JP2020512977A5 JP 2020512977 A5 JP2020512977 A5 JP 2020512977A5 JP 2019553068 A JP2019553068 A JP 2019553068A JP 2019553068 A JP2019553068 A JP 2019553068A JP 2020512977 A5 JP2020512977 A5 JP 2020512977A5
Authority
JP
Japan
Prior art keywords
cancer
subject
compound
combination according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512977A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/025464 external-priority patent/WO2018183891A1/en
Publication of JP2020512977A publication Critical patent/JP2020512977A/ja
Publication of JP2020512977A5 publication Critical patent/JP2020512977A5/ja
Pending legal-status Critical Current

Links

JP2019553068A 2017-03-31 2018-03-30 Chk1阻害剤とwee1阻害剤との組み合わせ Pending JP2020512977A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480101P 2017-03-31 2017-03-31
US62/480,101 2017-03-31
PCT/US2018/025464 WO2018183891A1 (en) 2017-03-31 2018-03-30 Combinations of chk1- and wee1 - inhibitors

Publications (2)

Publication Number Publication Date
JP2020512977A JP2020512977A (ja) 2020-04-30
JP2020512977A5 true JP2020512977A5 (enExample) 2021-05-13

Family

ID=62002508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553068A Pending JP2020512977A (ja) 2017-03-31 2018-03-30 Chk1阻害剤とwee1阻害剤との組み合わせ

Country Status (11)

Country Link
US (1) US20200108074A1 (enExample)
EP (1) EP3600247A1 (enExample)
JP (1) JP2020512977A (enExample)
KR (1) KR20190130621A (enExample)
CN (1) CN110678169A (enExample)
AU (1) AU2018243667A1 (enExample)
CA (1) CA3058457A1 (enExample)
IL (1) IL269409A (enExample)
MX (1) MX2019011506A (enExample)
SG (1) SG11201908788YA (enExample)
WO (1) WO2018183891A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074979A1 (en) 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
WO2019074981A1 (en) 2017-10-09 2019-04-18 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AND USES THEREOF
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP2022554157A (ja) * 2019-10-25 2022-12-28 アストラゼネカ・アクチエボラーグ がんを処置する方法
CN114207437B (zh) * 2020-02-27 2024-05-28 国立大学法人北海道大学 筛选抗癌剂的方法和用于治疗胰腺癌的激酶抑制剂的组合药物
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
CN115778962B (zh) * 2022-11-28 2024-09-17 中国医学科学院肿瘤医院 治疗男性食管癌患者的药物及其相关应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
EP0630234B1 (en) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003010444A1 (en) 2001-07-23 2003-02-06 Shock-Proof Solutions Pty Ltd Mechanical shock absorbing apparatus
BRPI0412820A (pt) 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
WO2005072733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Dyarylurea compounds as chk-1 inhibitors
EP1768977A2 (en) 2004-07-02 2007-04-04 ICOS Corporation Compounds useful for inhibiting chk1
JP2008510719A (ja) 2004-08-19 2008-04-10 イコス・コーポレイション Chk1の阻害に有用な化合物
HRP20100678T1 (hr) * 2005-03-29 2011-02-28 Icos Corporation Derivati heteroariluree korisni kao inhibitori chk1
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
CN101686675A (zh) 2007-03-20 2010-03-31 史密丝克莱恩比彻姆公司 化合物
CA2689429C (en) 2007-06-15 2012-08-21 Banyu Pharmaceutical Co., Ltd. Bicycloaniline derivatives
PA8850801A1 (es) 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
US8288396B2 (en) 2009-02-25 2012-10-16 Msdkk Pyrimidopyrimidoindazole derivative
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TW201304778A (zh) * 2010-11-16 2013-02-01 Array Biopharma Inc 檢查點激酶1抑制劑及wee1激酶抑制劑之組合
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
US8716297B2 (en) 2011-07-15 2014-05-06 Abbvie Inc. Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP2755482B1 (en) * 2011-09-15 2016-06-01 Merck Sharp & Dohme Corp. Combination of mk-1775 and mk-8776 for treating cancer
CA2851640A1 (en) 2011-10-20 2013-04-25 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
MX2014010176A (es) 2012-02-23 2014-11-10 Abbvie Inc Inhibidores de cinasas de piridopirimidinona.
JP6027230B2 (ja) * 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド 5−[[4−[[モルホリン−2−イル]メチルアミノ]−5−(トリフルオロメチル)−2−ピリジル]アミノ]ピラジン−2−カルボニトリルおよびその治療上の使用
GB201306610D0 (en) 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
GB201316024D0 (en) 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017216559A1 (en) 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2022017295A5 (enExample)
JP2022017296A5 (enExample)
JP2006503919A5 (enExample)
Guo et al. Neratinib for HER2-positive breast cancer with an overlooked option
JP2022516170A5 (enExample)
JP2019506392A5 (enExample)
JP5537035B2 (ja) Cdk阻害剤、および成長因子抗体または抗有糸分裂剤を含む組合せ
JP2019512478A5 (enExample)
JP2020515637A5 (enExample)
JP2017505321A5 (enExample)
JP2008535902A5 (enExample)
JP2016510748A5 (enExample)
JP2018511643A5 (enExample)
JP2021530487A5 (enExample)
JP6240083B2 (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
JP2010520280A5 (enExample)
JP2018534263A5 (enExample)
JP2017514800A5 (enExample)
JP2024125139A5 (enExample)
JP2019533652A5 (enExample)
JP2019534865A5 (enExample)
JP2023510736A5 (enExample)
JP2010534682A5 (enExample)
JP2020520923A5 (enExample)
WO2025061140A1 (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途